This is a randomized, multicenter phase II study of pembrolizumab in combination with
chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the
safety and efficacy of the combination of pembrolizumab with chemotherapy and chemoradiation
in locally advanced esophageal adenocarcinoma as assessed by 1 year disease free survival
rate. The investigators primary aim is to examine the safety and efficacy of pembrolizumab in
both pre-operative treatment paradigms for esophageal/GEJ carcinoma. The specific rationale
for the investigators study design is rooted in three unanswered questions:
1. does the addition of an immune check-point inhibitor (pembrolizumab) enhance the
efficacy of cytotoxic therapy (chemotherapy with chemoradiation) as determined by
response rates, nodal down-staging and 1 year disease free survival in comparison to
2. what are the pathological effects of combining pembrolizumab with chemotherapy alone,
3. what are the molecular (PD-L1 expression), immunological (TILs extent) and
gene-expression signatures associated with the efficacy of pembrolizumab in the
1. Patients must have histologically or cytologically confirmed esophageal or GEJ Siewert
type I or II adenocarcinomas
2. Clinical tumor stage should be T2-T4, N0-1, M0
3. Be willing and able to provide written informed consent/assent for the trial
4. Be 18 years of age or older on day of signing informed consent.
5. Be a candidate for surgical resection.
6. Be willing to provide tissue during endoscopic assessment of their tumor.
7. Have a performance status of 0 or 1 on the ECOG Performance Scale.
8. Demonstrate adequate organ function as defined below, all screening labs should be
performed within 14 days of treatment initiation.
- Absolute neutrophil count (ANC) ≥1,500 /mcL
- Platelets≥100,000 / mcL
- Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion within 7 days of assessment
- Serum creatinine OR Measured or calculated creatinine clearance ≤1.5 X upper
limit of normal (ULN) OR
- ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
(Creatinine clearance should be calculated per institutional standard) (GFR can
also be used in place of creatinine or CrCl)
- Serum total bilirubin ≤ 1.5 X ULN OR
- Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
- AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN
- Albumin >2.5 mg/dL
- International Normalized Ratio (INR) OR Prothrombin Time (PT) ≤1.5 X ULN unless
subject is receiving anticoagulant therapy as long as PT or PTT is within
therapeutic range of intended use of anticoagulants
- Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is
receiving anticoagulant therapy as long as PT or PTT is within therapeutic range
of intended use of anticoagulants
9. Female subject of childbearing potential should have a negative urine or serum
pregnancy within 7 days prior to receiving the first dose of study medication. If the
urine test is positive or cannot be confirmed as negative, a serum pregnancy test will
10. Female subjects of childbearing potential should be willing to use 2 methods of birth
control or be surgically sterile, or abstain from heterosexual activity for the course
of the study through 120 days after the last dose of study medication (Reference
Section 5.7.2). Subjects of childbearing potential are those who have not been
surgically sterilized or have not been free from menses for > 1 year.
11. Male subjects should agree to use an adequate method of contraception starting with
the first dose of study therapy through 120 days after the last dose of study therapy.
1. Is currently participating and receiving study therapy or has participated in a study
of an investigational agent and received study therapy or used an investigational
device within 4 weeks of the first dose of treatment.
2. Evidence of metastatic disease.
3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
other form of immunosuppressive therapy within 7 days prior to the first dose of trial
4. Has a known history of active TB (Bacillus Tuberculosis)
5. Hypersensitivity to pembrolizumab or any of its excipients.
6. Has had a prior anti-cancer treatment, including chemotherapy, radiation, or
monoclonal antibody (mAb).
7. Has a known additional malignancy that is active. Exceptions include basal cell
carcinoma of the skin or squamous cell carcinoma of the skin that has undergone
potentially curative therapy or in situ cervical cancer.
8. Has a previous invasive malignancy treated with curative intent less than 3 years from
time of registration. Exceptions include prostate cancer.
9. Has active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment.
10. Has known history of, or any evidence of active, non-infectious pneumonitis.
11. Has an active infection requiring systemic therapy.
12. Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the trial, interfere with the subject's
participation for the full duration of the trial, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator.
13. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
14. Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 120 days after the last dose of trial treatment.
15. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
17. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
[qualitative] is detected).
18. Has received a live vaccine within 30 days of planned start of study therapy. Note:
Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live
attenuated vaccines, and are not allowed.